Document is current
Any future updates will be listed below
-
Authors
Miravet-Verde, Samuel https://orcid.org/0000-0002-1542-5912
Cacace, Elisabetta https://orcid.org/0000-0001-8239-0353
Mores, Carine Roese
Rutschmann, Christoph https://orcid.org/0009-0004-0660-4283
Lin, Chia-wei https://orcid.org/0000-0003-4777-2916
Ruscheweyh, Hans-Joachim https://orcid.org/0000-0001-7473-6086
Cuénod, Aline
Barazzone, Elisa Cappio https://orcid.org/0000-0003-1295-4672
Marrec, Enora
Vershynina, Kateryna
Schumann, Raffael https://orcid.org/0000-0001-8401-4036
Bower, Dan J. https://orcid.org/0000-0002-0673-4860
Schubert, Mario https://orcid.org/0000-0003-0278-4091
Egli, Adrian
Fiebig, Timm https://orcid.org/0000-0002-2021-7296
Slack, Emma https://orcid.org/0000-0002-2473-1145
Sunagawa, Shinichi https://orcid.org/0000-0003-3065-0314
Keys, Timothy G. https://orcid.org/0000-0003-2921-0362
- License Information
-
More Information
Article History
Received: 25 September 2025
Accepted: 13 March 2026
First Online: 23 April 2026
Competing interests
: C.R., E.S. and T.G.K. are listed as inventors on a European patent application (EP24168910) describing methods and reagents for the preparation of capsule-targeting vaccines. C.R. and T.G.K. are founders and shareholders of Baxiva AG. The other authors declare no competing interests.
